<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471119</url>
  </required_header>
  <id_info>
    <org_study_id>WOLWO-CT-A1.0</org_study_id>
    <nct_id>NCT01471119</nct_id>
  </id_info>
  <brief_title>Sublingual Immunotherapy in Patients With Atopic Dermatitis</brief_title>
  <official_title>Usefulness and Safety of Sublingual Dermatophagoides Farinae Drops in Patients With Atopic Dermatitis:A Randomized,Double-blind,Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wolwo Bio-pharmaceutical Co. LTD.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First affiliated Hospital,Suzhou University,Suzhou,China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect and safety of sublingual Dermatophagoides Farinae Drops in adult
      patients with atopic dermatitis and allergic sensitization to house dust mites.240 adults age
      18 to 60 years with atopic dermatitis(Objective Scoring Atopic Dermatitis, Objective SCORAD
      from 10 to 40) are going to be enrolled in a randomized,double-blind,placebo-controlled
      study.Sublingual Dermatophagoides Farinae Drops or placebo is given for 9 months in addition
      to standard therapy.SCORAD,average anesis interval,rescue medicine and DLQI will be recorded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SCORAD is composed of skin rash area,severity and subjective symptom including pruritus and
      sleeping quality.Skin rash area and severity score are objective SCORAD(range from 0 to
      83).Subjective SCORAD range from 0 to 20 and total SCORAD range from 0 to 103.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>average anesis interval</measure>
    <time_frame>baseline and 36 week</time_frame>
    <description>The average duration of last 3 whole anesis interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rescue medication consumption</measure>
    <time_frame>36 week</time_frame>
    <description>The total sum of rescue medication consumption will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SCORAD</measure>
    <time_frame>baseline and 36 week</time_frame>
    <description>Change of SCORAD will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DLQI</measure>
    <time_frame>baseline and 36 week</time_frame>
    <description>Change of Dermatology Life Quality Index will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Dermatophagoides Farinae Drops Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dermatophagoides Farinae Drops Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drops of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dermatophagoides Farinae Drops Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo Group is the group with maintenance dose of 3 drops of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dermatophagoides Farinae Drops Group 1</intervention_name>
    <description>Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.</description>
    <arm_group_label>Dermatophagoides Farinae Drops Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dermatophagoides Farinae Drops Group 2</intervention_name>
    <description>Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.</description>
    <arm_group_label>Dermatophagoides Farinae Drops Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dermatophagoides Farinae Drops Group 3</intervention_name>
    <description>Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.</description>
    <arm_group_label>Dermatophagoides Farinae Drops Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Group is the group with maintenance dose of 3 drops of placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of either sex ,aged from 18 to 60 years. Diagnosed of atopic dermatitis.

          -  Mild to moderate AD ( [SCORAD] 1O-40)

          -  The results of skin prick tests with dermatophagoides farinae allergen extracts
             preparation is positive(≥2+)

          -  Written informed consent by the subject or legal guardian.

          -  Female patients of child-bearing potential must be negative pregnant test on screening
             and use an appropriate method of contraception.

        Exclusion Criteria:

          -  Dust mites are not the primary allergens.

          -  Pregnant, breastfeeding women or women planned to pregnant within 1 year.

          -  Have concurrent skin disease that it could interfere with the study evaluation.

          -  Were treated with antihistamines or topical therapy within 7 days of randomization.

          -  Have received systemic corticosteroids,leukotriene receptor antagonists or
             immunosuppressants within 4 weeks of randomization.

          -  Have received phototherapy (e.g. UVA, UVB) within 4 weeks of randomization.

          -  Have a history of immune suppressed diseases(malignant tumor or infection of HIV),
             autoimmune disease or tuberculosis.

          -  Patients with impaired liver function (aspartate aminotransferase and/ or alanine
             aminotransferase levels 1.5 times the upper limit of normal), impaired renal
             function(serum creatinine＞normal value) or other severe diseases.

          -  Bronchial asthma patients who need treatments with corticosteroids and or β
             agonists(including injection, oral administration or inhalation) regularly.

          -  Patients who need to take β-blockers during research.

          -  Have received investigational drugs within 3 months prior to randomization or planned
             use of other investigational drugs during participation in this study.

          -  Have received immunotherapy with dust mite preparation within 3 years prior to
             randomization.

          -  Patients with severe mental disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Zheng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Second Affiliated Hospital,School of Medicine,Zhejiang University.</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Min Zheng</investigator_full_name>
    <investigator_title>Director of dermatology department,Professor</investigator_title>
  </responsible_party>
  <keyword>sublingual immunotherapy</keyword>
  <keyword>atopic dermatitis</keyword>
  <keyword>Dermatophagoides Farinae Drops</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

